Code intelligence

FDA-NDA206769 reimbursement alerts

Policy changes, MAC LCD updates, and CMS guidance referencing code FDA-NDA206769.

Critical code risk

Signal breakdown

1 shown · 1 total in platform

Risk: Critical
1

Critical

100%

0

High

0%

0

Routine

0%

0

Low

0%

New this month

+1

alerts added in last 30 days

Effective soon

no upcoming deadlines

FDA Approval: ARGATROBAN IN 0.9% SODIUM CHLORIDE (ARGATROBAN) — Type 5 - New Formulation or New Manufacturer

Policy FDA-NDA206769 · Hematology

Critical

Argatroban in 0.9% Sodium Chloride (NDA206769) is a new intravenous formulation of the established direct thrombin inhibitor argatroban, approved via a Type 5 submission by Teva Pharmaceuticals. As an